AU Patent

AU2018379306A1 — Combination therapy of multiple sclerosis comprising a CD20 ligand

Assigned to Mabion SA · Expires 2020-06-25 · 6y expired

What this patent protects

The present invention relates to the use of a CD20 ligand and at least one further active agent in the treatment of multiple sclerosis, to the use of a pharmaceutical composition and to a kit comprising the CD20 ligand and at least one further active agent or a pharmaceutical com…

USPTO Abstract

The present invention relates to the use of a CD20 ligand and at least one further active agent in the treatment of multiple sclerosis, to the use of a pharmaceutical composition and to a kit comprising the CD20 ligand and at least one further active agent or a pharmaceutical composition comprising such CD20 ligand and further active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018379306A1
Jurisdiction
AU
Classification
—
Expires
2020-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Mabion SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.